UCR 280: Testosterone Pellet Denials, Secondary Payer Prior Auths, and Urology Risk Assessments
About this episode
The episode discusses reimbursement challenges in urology, focusing on testosterone pellet denials, secondary payer prior authorizations, and urology risk assessments.
March 13, 2026 In this episode, Scott, Mark, and Dr. Ray Painter tackle three emerging reimbursement challenges affecting urology practices: widespread denials for testosterone pellet (Testopel®) therapy, the growing trend of secondary payers requiring prior authorization for high-cost drugs, and whether urology questionnaires qualify as billable health risk assessments. PRS Coding and Reimbursement Hub Access the Hub Botox LCD Alert Download the Alert Free In-Office Pros...
People in this episode
Hosts: Scott Painter, Mark Painter, Dr. Ray Painter
Topics covered
- testosterone therapy
- reimbursement challenges
- prior authorization
- urology risk assessments
- healthcare coding
Keywords
- testosterone pellet
- reimbursement
- prior authorization
- urology
- health risk assessments
- coding
- healthcare
Mentioned in this episode
Products: Testopel®
More episodes of Urology Coding and Reimbursement Podcast
- UCR 288: New Technology in Urology – Don’t Let Reimbursement Be an Afterthought
- UCR 286: C9761 Clarified – What Actually Qualifies and What’s at Risk
- UCR 285: Bringing More Complex Procedures Into the Office – Is It Worth It?
- UCR 284: UTI PCR Under Fire – OIG Scrutiny, Denials, and What to Do Next
- UCR 283: Saturation Biopsy Confusion and Cystoscopy Risk—Where Interpretation Matters
- UCR 282: Playing the Surgical Lottery – Medicare Advantage and Out-of-Network Strategy
Explore listener stats, chart rankings, contacts and more on the Urology Coding and Reimbursement Podcast podcast page.